Korean Botox

Korean Botulinum Toxin Manufacturers: Hugel, Medytox, Daewoong & Huons

Korean botulinum toxin type A is commonly referenced in clinical procurement contexts as what is Korean Botox, describing a category of injectable neurotoxins manufactured in South Korea and widely used across aesthetic medicine. The rise of Korean Botox in global markets reflects the expanding adoption of GMP-certified production standards, diversified formulations, and competitive manufacturing efficiency.

The category now includes a full product range spanning liquid and lyophilized neurotoxins designed for expression lines, forehead lines, and other common treatment areas. This segment of injectable neurotoxins has become a structured wholesale category across international aesthetic supply chains.

For professionals evaluating Korean Botox brands, two frameworks are particularly important: manufacturer-to-brand mapping and formulation type. Understanding who manufactures each product and whether it is supplied as a ready-to-use liquid or a lyophilized powder can simplify sourcing decisions and inventory planning.

Manufacturer-to-Brand Mapping: A Procurement Reference

From a procurement perspective, manufacturer identity matters because it influences quality systems, regulatory history, production consistency, and long-term supply considerations. The South Korean manufacturers include:

Hugel manufactures:

• LETYBO™
• BOTULAX®

Medytox manufactures:

• INNOTOX®
• MEDITOXIN®

Daewoong manufactures:

• NABOTA® (marketed in the United States as Jeuveau® through Evolus)

Huons manufactures:

• LIZTOX®

Additional products available in the broader Korean botulinum toxin category include Re N Tox® and KAIMAX®, which are distributed in selected international markets.

For clinics comparing a specific Korean Botox brand, the manufacturer background often serves as a starting point for evaluating clinical literature, regulatory status, and available documentation.

Formulation Type: The Primary Differentiator

One of the most important distinctions among Korean injectable neurotoxins is formulation type.

INNOTOX®: Liquid, Ready-to-Use Formulation

INNOTOX® remains unique within the category because it is supplied as a liquid formulation. Unlike traditional powder products, it does not require reconstitution before administration.

Key characteristics include:

• Ready-to-use presentation
• Available in 50-unit and 100-unit configurations
• Refrigerated storage at 2-8°C
• Reduced preparation steps
• Consistent preparation workflow

For high-volume practices, eliminating reconstitution may help reduce variability during preparation and improve operational efficiency.

Lyophilized Korean Botulinum Toxin Products

Most other Korean botulinum toxin products are supplied as lyophilized powders, including:

• BOTULAX®
• NABOTA®
• MEDITOXIN®
• Re N Tox®
• KAIMAX®
• LIZTOX®

These products require reconstitution with sterile normal saline according to the manufacturer labeling before administration. The concentration ultimately used in practice depends on the selected dilution protocol and brand-specific guidance.

Although reconstitution introduces an additional preparation step, many clinics remain comfortable with lyophilized formulations because they align with established neurotoxin workflows already used across aesthetic medicine.

What Is Korean Botox and Why Has Global Demand Increased?

Korean botulinum toxin products are derived from Clostridium botulinum and function through the same core mechanism as other botulinum toxin type A products used worldwide. Following administration, the neurotoxin temporarily inhibits acetylcholine release at the neuromuscular junction, reducing activity in the targeted facial muscles.

This mechanism supports a broad range of neurotoxin aesthetic treatment protocols involving:

• Glabellar lines
• Forehead lines
• Crow’s feet
• Lines between the eyebrows
• Perioral concerns
• Masseter treatment
• Other common treatment areas involving dynamic wrinkles and lines

The continued rise of Korean Botox can largely be attributed to three factors:

• Manufacturing Standards: Major manufacturers operate GMP-compliant facilities and maintain quality assurance systems that meet international pharmaceutical standards.
• Formulation Diversity: The category includes both traditional lyophilized products and the only commercially recognized liquid formulation, INNOTOX®.
• Expanding International Presence: Many Korean manufacturers have pursued approvals and commercial expansion beyond South Korea, contributing to broader recognition of Korean botulinum toxin products among licensed practitioners.

As a result, Korean Botox has become a recognized wholesale category rather than simply a regional alternative.

Is Korean Botox Safe?

Published clinical literature supports safety and efficacy profiles for approved botulinum toxin type A products when manufactured under GMP conditions and used according to labeled instructions.

Safety evaluations should focus on several factors:

• Manufacturer reputation
• Published clinical data
• Batch traceability
• GMP certification
• Regulatory oversight within the intended market
• Availability of certificates of analysis

Several published studies have examined the performance and safety of botulinum toxin type A. Research by Carruthers et al. in Dermatologic Surgery (2015) reported sustained efficacy and tolerability with repeated botulinum toxin type A treatments for glabellar and crow’s-feet lines. Additional clinical literature has supported the safety profile of modern injectable neurotoxins used for aesthetic indications.

For clinics working with Korean Botox suppliers, documentation remains just as important as clinical performance. Procurement teams should verify manufacturer records, lot-number traceability, cold-chain handling procedures, and available quality-control documentation before finalizing sourcing decisions. To order Korean botox online, practitioners must provide a valid license.

Full Brand Catalogue: LETYBO™, INNOTOX®, BOTULAX®, NABOTA®, MEDITOXIN® & More

While all products within the category contain botulinum toxin type A, they differ in formulation, vial size, manufacturer, and regulatory standing. Understanding these distinctions can help practitioners identify products that align with clinical workflows, patient volume, and jurisdictional requirements.

LETYBO™ (Hugel)

LETYBO™ is a lyophilized botulinum toxin type A manufactured by Hugel. The product is supplied in 50-unit and 100-unit vial configurations and is commonly discussed in relation to glabellar lines and forehead lines.

For practitioners asking what LETYBO is or who makes LETYBO, the answer is straightforward: LETYBO™ is manufactured by Hugel, one of South Korea’s most established aesthetic pharmaceutical companies.

Current regulatory information indicates that LETYBO™ received FDA approval in the United States in 2024 (current as of mid 2026), making it one of the most widely recognized Korean Botox products available internationally.

INNOTOX® (Medytox)

INNOTOX® is manufactured by Medytox and remains the category’s defining liquid formulation. Available in both 50-unit and 100-unit presentations, it requires no reconstitution before administration. This distinction has made it particularly attractive to clinics seeking preparation efficiency and simplified workflow management.

With practitioners frequently asking what Innotox is, INNOTOX® is a botulinum toxin type A product. Clinical evaluations addressing is Innotox safe confirm comparable efficacy and tolerability to lyophilized formulations, as supported by published clinical data and established manufacturing controls. Its liquid presentation differentiates it from every other major Korean botulinum toxin currently available.

For practices evaluating workflow efficiency, innotox injections may offer logistical advantages by eliminating the preparation step required for lyophilized products.

BOTULAX® (Hugel)

BOTULAX® is a lyophilized botulinum toxin type A manufactured by Hugel and supplied in 100-unit and 200-unit vial configurations. For clinics managing high patient throughput, the 200-unit presentation is often considered operationally efficient due to reduced vial handling and inventory turnover.

From a procurement standpoint, BOTULAX® is frequently evaluated alongside other high-volume Korean Botox brands because it originates from the same manufacturer as LETYBO™, offering continuity in production oversight while serving a different international regulatory segment.

NABOTA® (Daewoong)

NABOTA® (prabotulinumtoxinA-xvfs) is a lyophilized formulation manufactured by Daewoong and supplied in 100-unit vials. It is also marketed in the United States as Jeuveau®.

For practitioners comparing FDA-approved Korean Botox options, NABOTA® is among the most established products with U.S. regulatory approval (as of mid 2026). Its clinical development includes published randomized controlled trial data supporting efficacy in glabellar line treatment.

MEDITOXIN® (Medytox)

MEDITOXIN® is a lyophilized botulinum toxin type A product manufactured by Medytox and offered in 100, 150, and 200-unit vial strengths. This range allows clinics to adjust procurement volume based on patient demand and treatment frequency.

In practice, MEDITOXIN® is often chosen by providers seeking flexibility in dosing protocols, particularly in practices that treat multiple facial areas, including forehead lines, crow’s feet, and lines between the eyebrows.

Re N Tox®, LIZTOX®, and KAIMAX®

Re N Tox® is a lyophilized botulinum toxin product available in select international markets, but it is not FDA-approved (as of mid 2026). It remains approved in South Korea and certain jurisdictions.

LIZTOX® is manufactured by Huons and supplied in a 100-unit lyophilized format. Like most non-U.S. Korean botulinum toxin products, it is approved in South Korea and other international markets but is not FDA-approved for U.S. use (as of mid 2026).

KAIMAX® is an emerging lyophilized neurotoxin option within the broader Korean botulinum toxin category, positioned primarily for international distribution channels.

Botox Units, Reconstitution Protocol & Storage Temperature: Procurement Essentials

Understanding Botox Units

Botulinum toxin units measure biological activity at the neuromuscular junction and are not interchangeable across brands. A 100-unit vial of one Korean botulinum toxin product does not equate clinically to 100 units of another brand or a Western formulation.

This distinction is important when evaluating dosing consistency across aesthetic injectable protocols involving facial muscles and expression lines. Each manufacturer calibrates unit potency based on its own clinical development data.

Most Korean Botox brands are supplied in:

• 100-unit vials (standard)
• 200-unit vials (high-volume practices)

200-unit configurations, such as those found in BOTULAX® and MEDITOXIN®, are often used in clinics with higher patient throughput.

Reconstitution and Preparation

Lyophilized Korean botulinum toxin products require reconstitution using sterile, non-bacteriostatic normal saline prior to administration. The final concentration is determined by the dilution volume and must comply with each manufacturer’s labeling.

By contrast, INNOTOX® is supplied as a liquid formulation and does not require reconstitution. This removes a procedural step and may reduce variability in preparation within clinical workflows.

Storage and Cold Chain Requirements

Both liquid and lyophilized Korean Botox products require refrigerated storage between 2-8°C throughout distribution and clinic storage.

Key handling considerations include:

• Maintaining cold-chain integrity during transport
• Avoiding exposure to light and heat
• Following manufacturer-specific post-reconstitution stability windows
• Using lyophilized products typically within 24 hours after preparation (verify per label)

Practitioners reviewing Korean Botox suppliers should confirm that cold-chain logistics and storage documentation are clearly defined before procurement.

Common Treatment Areas and Duration

Korean botulinum toxin products are widely used for aesthetic protocols involving:

• Glabellar lines
• Forehead lines
• Crow’s feet
• Lines between the eyebrows
• Perioral lines
• Masseter muscle reduction

Treatment outcomes typically last between 3 and 6 months, depending on the patient’s metabolism, muscle activity, and prior exposure to neurotoxin aesthetic treatments.

Is Korean Botox FDA-approved? Regulatory Status for Wholesale Buyers

FDA Approval Overview (Current as of mid 2026)

Only two Korean botulinum toxin brands currently hold FDA approval for the U.S. market:

• LETYBO™ (Hugel): FDA-approved in 2024 (current as of mid 2026)
• NABOTA® / Jeuveau® (Daewoong): FDA-approved and marketed by Evolus Inc.

All other Korean Botox brands, including INNOTOX®, BOTULAX®, MEDITOXIN®, Re N Tox®, LIZTOX®, and KAIMAX®, are approved in South Korea and select international markets but are not FDA-approved for U.S. use (current as of mid 2026).

Regulatory Considerations for Procurement

When buying online, regulatory compliance should be assessed on a jurisdiction-specific basis. FDA approval is only one component of procurement decision-making.

Practitioners should also consider:

• Manufacturer GMP certification
• Lot number traceability
• Certificates of analysis
• Cold-chain documentation
• Clinical data availability

Medica Depot support representatives assist with documentation-related guidance and verification resources to help practitioners evaluate compliance requirements across different markets.

Comparing Korean Botox Brands: Best Korean Botulinum Toxin for Your Practice

No Single Best Product

There is no universal “best” Korean botulinum toxin. Selection depends on clinical workflow, patient demographics, treatment areas, and procurement preferences.

Rather than ranking products, it is more practical to compare operational advantages.

INNOTOX® vs NABOTA®

Both are widely used 100-unit formulations but differ significantly in preparation and regulatory profile.

INNOTOX® advantages:

• Liquid formulation
• No reconstitution required
• Reduced preparation time
• Simplified workflow for high-volume clinics

NABOTA® advantages:

• FDA-approved (Jeuveau®)
• Strong Western clinical trial support
• Established regulatory positioning
• Lyophilized stability

Both are effective botulinum toxin type A products when used according to brand-specific dosing protocols.

BOTULAX® vs MEDITOXIN®

Both are high-volume lyophilized options designed for scalable clinical use.

BOTULAX® advantages:

• Manufactured by Hugel (same parent company as LETYBO™)
• Available in 200-unit vials
• Consistent manufacturing lineage

MEDITOXIN® advantages:

• Multiple vial strengths (100, 150, 200 units)
• Long-standing export history from South Korea
• Flexible inventory planning

Where Can Practitioners Buy Korean Botox Online?

Korean Botox is available only to qualified professionals. Licensed aesthetic clinics, dermatology practices, and compounding pharmacists evaluating buy Korean Botox online or buy Korean Botox wholesale pathways should prioritize suppliers that provide:

• Verified purity documentation
• Lot number traceability
• Certificates of analysis
• Cold-chain handling verification
• Manufacturer credential transparency

When sourcing Korean botulinum toxin products, it is also recommended to check for wholesale buying options that align with clinical volume requirements and regulatory jurisdiction.

Medica Depot provides guidance and documentation support through its support representatives, assisting practitioners in reviewing manufacturer data, regulatory information, and procurement documentation frameworks. Final sourcing decisions remain under the responsibility of licensed practitioners.

FAQs

1. What is the full range of Korean Botox brands available wholesale?

The category includes LETYBO™, BOTULAX®, INNOTOX®, MEDITOXIN®, NABOTA®, LIZTOX®, Re N Tox®, and KAIMAX®. These span both liquid and lyophilized formulations with vial sizes ranging from 50 to 200 units, depending on the manufacturer.

2. What is the difference between liquid and lyophilized Korean Botox for procurement?

Liquid formulations (INNOTOX®) require no reconstitution and are ready for administration. Lyophilized products require dilution with sterile saline before use. Both require cold-chain storage at 2-8°C.

3. Which Korean Botox brands are approved for the US market?

LETYBO™ (Hugel) and NABOTA®/Jeuveau® (Daewoong) are FDA-approved (current as of mid 2026). Other brands are not FDA-approved in the U.S.

4. What do Botox units mean, and are Korean Botox units the same as Western brands?

Units measure biological activity and are not interchangeable across brands. Each manufacturer defines potency based on its own clinical calibration.

5. Who manufactures LETYBO, and is it the same as BOTULAX?

Both are manufactured by Hugel, but they are distinct products with different regulatory approvals and formulations.

6. What is INNOTOX, and what makes it different?

INNOTOX® is a liquid botulinum toxin manufactured by Medytox that requires no reconstitution and is ready to use from refrigeration.

7. How should Korean Botox be stored?

Most products require storage at 2-8°C. Lyophilized products require reconstitution before use, while INNOTOX® does not.

References

1. Dressler D, Kim N, Johnson EA, Adib Saberi F. Korean botulinum toxins. J Neural Transm (Vienna). Published online January 31, 2026. doi:10.1007/s00702-025-03076-x
2. Frevert J, Ahn KY, Park MY, Sunga O. Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol. 2018;11:327-331. Published 2018 Jul 5. doi:10.2147/CCID.S160723
3. Verdin P. FDA new drug approvals in Q1 2024. Nat Rev Drug Discov. 2024;23(5):331. doi:10.1038/d41573-024-00063-x

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.